Interestingly, a recent study shows a lower risk of developing high-grade PCa for men with low serum cholesterol levels [32] and, in line with this, long-term use of HMG-CoA reductase inhibitors (“statins”) for prevention of cardiovascular disease have been shown to reduce the risk of PCa progression into aggressive, fatal disease [33], [34], [35], [36]. The gene discussed is HMGCR; the disease is cardiovascular disorder.